Spyre Therapeutics, Inc. (SYRE) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Clinical remission — SPY001 | 40.00 percent | FY2026-Q2 |
| Endoscopic improvement — SPY001 | 51.00 percent | FY2026-Q2 |
| Pro forma cash, cash equivalents, and marketable securities | 1.18B | FY2026-Q1 |
| Healthy adult participants | 40.00 | FY2025-Q2 |
| SPY003 half-life | 85.00 | FY2025-Q3 |
| Non-cash stock-based compensation expense | 9.4M | FY2025-Q2 |
| Gross proceeds | 463M | FY2026-Q1 |
Back to SYRE overview · SYRE earnings · SYRE holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.